Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I5NP dose-escalation study for prevention of delayed graft function after deceased donor kidney transplantation
2010-020989-20Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Nov 2010
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of teprasiran in delayed graft function (DGF) (2 arms), sponsored by Quark Pharmaceuticals. Primary endpoint: Incidence of delayed graft function. Started Nov 2010; status: completed.
02
Drugs
teprasiran
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2010-020989-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020989-20.